News | September 02, 2008

Study Shows DES Improves Survivial in STEMI Patients

September 2, 2008 - The safety debate about drug-eluting stents (DES) is still ongoing and in these times of uncertainty about DES safety, a new study has shown DES markedly improves long-term survival, compared to modern bare-metal stents (BMS) in patients with acute ST-segment elevation myocardial infarction (STEMI).

Dr. Thorsten Grumann, of the University of Freiburg Department of Cardiology in Germany, explained the results of his study at the European Society of Cardiology 2008 Congress today. He said in the four-year investigation, DES demonstrated a significant reduction of mortality in this sick patient subset.
The study sought to present a subgroup analysis of patients with myocardial infarction followed long-term for a mean of four years in the Freiberg Stent Registry (FRIST), a single-centre registry in high volume tertiary referral cardiovascular centre. FRIST included complex coronary patients treated with DES and BMS in the University Hospital of Freiburg, Germany, according to nonselected inclusion criteria. For the first time, three drug eluting stents, namely Cypher, Taxus and Endeavor, were compared. The DES-groups were matched to a historical, contemporary BMS control group.

The primary study endpoint was overall survival. Cardiac and noncardiac death was also analyzed.

“We observed a significant survival benefit of patients who received DES compared with patients who received BMS in FRIST,” Dr. Grumann said.

The overall crude incidence for all-cause death was 7 percent (13 out of 186) in the DES-group and 24 percent (27 out of 112) in the BMS-group. Applying a multivariate Cox survival model with adjustment for existing baseline differences between the patient groups resulted in a relative risk of 0.42. That implies a 58 percent decrease of mortality risk in the DES population within the four-year observation period. The adjusted risk reduction with respect to cardiac death (-70 percent) was even more impressive. A number needed to treat analysis (NNT) looking at mortality indicated that if 30 patients were treated with a DES instead of a BMS in STEMI, one life could be saved.

“The analysis clearly favors DES implantation with a marked long term survival benefit in patients with myocardial infarction over BMS,” said Dr. Grumann.

Reduced total mortality for DES as compared to BMS, and a further reduction with respect to cardiac death suggests many patients can profit from “off-label” use of DES. Dr. Grumann said the registry shows for the first time that DES are not only equal, but superior to BMS when long-term survival is the primary concern in patients with STEMI. The data supports the TYPHOON-results but should be interpreted with caution until further randomized mortality trials have substantiated the reported findings.

For more information: [email protected]

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init